Sign in
Not yet taking people in ItalyPhase 1

Peptide vaccine plus nivolumab for advanced melanoma that stopped responding to immunotherapy

Tests a melanoma vaccine with nivolumab in adults whose melanoma resisted immunotherapy.

Key facts

Who runs it
Humanitas Mirasole S.p.A.
Where
Milan, Naples, Padova, Perugia, and Rozzano, ItalySee the 5 sites
Registry title
A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients
Status
Not yet recruiting
Phase
Phase 1
People taking part
25 people, planned
Started
31 Oct 2026
Expected to end
31 Oct 2029
Type of study
Interventional
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that has spread or cannot be removed by surgery, and that no longer responds to immune checkpoint blocker treatment. It tests a melanoma peptide vaccine (UniCanVax) together with nivolumab.

Age
18 years or older
Sex
All sexes can join
Disease stage
Metastatic or unresectable stage III/IV melanoma that is refractory to immune checkpoint blockade
Earlier treatment
Previous immune checkpoint blocker treatment that no longer works (refractory)

Where in Italy

  • Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyNot yet recruiting
  • IRCCS Istituto Nazionale Tumori Fondazione PascaleNaples, ItalyNot yet recruiting
  • Istituto Oncologico VenetoPadova, ItalyNot yet recruiting
  • Azienda Ospedaliera di PerugiaPerugia, ItalyNot yet recruiting
  • Humanitas Mirasole S.p.A.Rozzano, ItalyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Peptide vaccine plus nivolumab for advanced melanoma that stopped responding to immunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 November 2026